We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Pcas Sa | LSE:0NF7 | London | Ordinary Share | FR0000053514 | PCAS ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 18.30 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2022 to Jul 2024
Ecully, May 25th, 2023
PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation
PCAS (Euronext Paris: PCA), specialized in the development of processes and production of complex molecules for Life Sciences and Specialty Chemicals Markets, has made the decision to sell PCAS Canada Inc., the Canadian subsidiary of PCAS Group, to DIC Corporation, a Japanese chemicals group with a presence in more than 60 countries.
An enterprise value of 88.2 million euros has been agreed for PCAS Canada Inc.
This decision has been made following the receipt of an offer from DIC Corporation for the acquisition of the Canadian subsidiary announced on May 2nd, 2023 (https://www.pcas.com/). This offer has been accepted by PCAS following the authorization of its Board of Directors. The competent workers’ council has been previously informed and consulted in accordance with applicable regulations.
The sale is not subject to any condition precedents. Therefore, the execution of the related agreements by PCAS and DIC Corporation as well as the closing of the transaction will be completed within the coming days.
ABOUT PCAS
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With about 11% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €226.4 million in 2022 and employs nearly 1200 people in six countries.
To find out more about PCAS: www.pcas.com
| PCAS | NewCap |
| Jean-Louis Martin / Eric Moissenot | Emmanuel Huynh / Louis-Victor Delouvrier NewCapFinancial communication and investor relation |
| Tel.: +33 1 69 79 60 00www.pcas.com | Tel.: +33 1 44 71 98 53pcas@newcap.eu |
Attachment
1 Year Pcas Chart |
1 Month Pcas Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
